Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Work
Year: 2015
Type: article
Abstract: In a phase 1 dose-escalation study, combined inhibition of T-cell checkpoint pathways by nivolumab and ipilimumab was associated with a high rate of objective response, including complete responses, a... more
Source: New England Journal of Medicine
Authors Michael A. Postow, Jason Chesney, Anna C. Pavlick, Caroline Robert, Kenneth F. Grossmann +16 more
Institutions Memorial Sloan Kettering Cancer Center, Cornell University, University of Louisville, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, New York University +14 more
Cites: 29
Cited by: 2,633
Related to: 10
FWCI: 207.5
Citation percentile (by year/subfield): 100
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: bronze